The Q-Line Biotech IPO has made a significant impact on its opening day, with subscriptions exceeding two times the issue size, particularly driven by non-institutional investors (NIIs).
Launched on May 21 and set to conclude on May 25, the IPO is priced between ₹326 and ₹343 per share, with a minimum bid for 400 shares. Q-Line Biotech, established in 2010, specializes in the development and distribution of diagnostic reagents, kits, and point-of-care devices, catering to healthcare needs through various products, including in-vitro diagnostics.
Financially, Q-Line Biotech reported a profit of ₹38.7 crore and revenue of ₹232.4 crore for the nine months ending December 2025, despite a year-over-year profit decline due to exceptional losses. The IPO aims to raise ₹214.48 crore, with a significant portion allocated to working capital and debt repayment.
The grey market premium (GMP) for the IPO is currently at +135, indicating strong investor interest and a projected listing price of ₹478, which is over 39% higher than the maximum IPO price. With a subscription status of 2.44 times on its first day, the retail and institutional segments are showing robust engagement, suggesting a positive market reception for Q-Line Biotech’s shares.
This IPO reflects the growing investor confidence in the life sciences sector, particularly in companies focused on diagnostics, which are increasingly vital in today’s healthcare landscape. As the demand for innovative diagnostic solutions continues to rise, Q-Line Biotech's successful entry into the public market could signal further growth opportunities in the biotech space.